V-ATPase inhibitors and implication in cancer treatment.
about
pH sensing and regulation in cancerRotating with the brakes on and other unresolved features of the vacuolar ATPaseEvolution of increased complexity in a molecular machineInhibitory and combinatorial effect of diphyllin, a v-ATPase blocker, on influenza viruses.Elucidation of how cancer cells avoid acidosis through comparative transcriptomic data analysis.Effects of omeprazole in improving concurrent chemoradiotherapy efficacy in rectal cancerExpression and Transcriptional Regulation of Human ATP6V1A Gene in Gastric Cancers.In vivo pH in metabolic-defective Ras-transformed fibroblast tumors: key role of the monocarboxylate transporter, MCT4, for inducing an alkaline intracellular pH.Anticancer targets in the glycolytic metabolism of tumors: a comprehensive reviewA human genome-wide screen for regulators of clathrin-coated vesicle formation reveals an unexpected role for the V-ATPase.Mutations in the proteolipid subunits of the vacuolar H+-ATPase provide resistance to indolotryptoline natural products.Utilizing hydrogen sulfide as a novel anti-cancer agent by targeting cancer glycolysis and pH imbalance.Microenvironmental acidosis in carcinogenesis and metastases: new strategies in prevention and therapy.Total synthesis of iejimalide B.The H(+) vacuolar ATPase maintains neural stem cells in the developing mouse cortex.New mode of action for a knottin protein bioinsecticide: pea albumin 1 subunit b (PA1b) is the first peptidic inhibitor of V-ATPaseNaphthalene diimides as red fluorescent pH sensors for functional cell imaging.Vacuolar ATPase 'a2' isoform exhibits distinct cell surface accumulation and modulates matrix metalloproteinase activity in ovarian cancerSpatial profiles of markers of glycolysis, mitochondria, and proton pumps in a rat glioma suggest coordinated programming for proliferation.Yeast homologous recombination-based promoter engineering for the activation of silent natural product biosynthetic gene clusters.Enoxacin directly inhibits osteoclastogenesis without inducing apoptosisTwelve-membered macrolactones: privileged scaffolds for the development of new therapeutics.The vacuolar H+ ATPase is a novel therapeutic target for glioblastoma.Inhibitors of vacuolar ATPase proton pumps inhibit human prostate cancer cell invasion and prostate-specific antigen expression and secretion.Painful boney metastases.Targeting the metabolic microenvironment of tumors.Lactoferrin selectively triggers apoptosis in highly metastatic breast cancer cells through inhibition of plasmalemmal V-H+-ATPase.MR evaluation of response to targeted treatment in cancer cells.Targeting reversible disassembly as a mechanism of controlling V-ATPase activityCurrent trends in miRNAs and their relationship with oral squamous cell carcinoma.Metabolic symbiosis in cancer: refocusing the Warburg lens.An update in the structure, function, and regulation of V-ATPases: the role of the C subunit.Cancer-associated lysosomal changes: friends or foes?Synthesis of cytotoxic palmerolides.Dysregulated pH in Tumor Microenvironment Checkmates Cancer Therapy.Design and synthesis of analogues of natural products.Total syntheses of the archazolids: an emerging class of novel anticancer drugs.Complete elucidation of the late steps of bafilomycin biosynthesis in Streptomyces lohii.Systematic identification of genes involved in metabolic acid stress resistance in yeast and their potential as cancer targets.Enantiospecific Synthesis and Cytotoxicity Evaluation of Oximidine II Analogues.
P2860
Q21129239-DE109CDE-74DA-4A4D-AAF4-2367D357A6D9Q26747183-01AC6462-24D0-4998-BEDC-C148905488F1Q29545093-F32A8921-5F43-4C4B-AD41-62E5268A2108Q30432662-A2ACFB47-93CC-4A8B-81CC-276280C045A8Q30662860-BD6D9033-46B1-44DD-8387-158FC3F823E6Q33572677-FEB950F6-35CF-4886-98E8-4A6E2B55170DQ33774231-DE789564-FCAC-4868-A685-3B8B1D4DBC25Q33870048-344475E0-DFF0-49E2-BC91-D8C822D097C7Q34028478-210D2006-0192-4305-9DFC-7968DB6F79BDQ34319285-DBB0DDC8-0A19-4D6A-90FD-EF10A33C6903Q34548618-AA0AA368-C804-45D7-9694-3B4026717938Q34559610-C6D109F6-E06B-49A4-9807-A6ED51FDC2E1Q34573748-1F1A6324-2270-49CA-9630-917A4738DBE7Q35068719-556FDD9D-7D91-4509-8B40-61E4A424550DQ35084123-48CCCD7C-913C-459D-89BC-F3685453076FQ35378072-87A332AC-CC1F-457F-8B6C-C745802EFB72Q35404062-EB767EA7-8369-44C8-AA50-B6AA46EA3D76Q35551874-8038C31F-ECE9-44BB-AB02-A8DD805FAA47Q35648960-4D06FF85-4B30-4B6F-9773-BCF9F72B7DE5Q35895616-09F31B93-D32F-421E-BF1B-1B2B36088520Q36006859-0AC41C9A-5F30-45AF-BA39-51FBAC8373F8Q36011215-014722C7-681A-4DD6-8D32-7EC162601848Q36232092-BA2A9A82-D6B2-4A37-84B8-78408010F4B7Q36417407-1C72DAB5-9742-4C5A-A868-13C289643E3CQ37011060-5576A30A-F91A-49F7-BA01-EB2D7876329BQ37229190-824E8B7B-F490-4198-A726-578DF0EE3A7EQ37641745-C8FEEE02-2C4A-42E5-9C3B-44E171056742Q37851076-CCDE5F37-633E-4029-9FF2-2B3AE804CB41Q37951590-3B1ECCB6-6F8F-45C1-AF38-9CC5FB3ED397Q37970449-E7C3A487-10F2-472D-9538-CD4C657A20BBQ37974107-D7EEE6A5-AB70-4ACF-BFA2-D664E46420E8Q37995893-6CCB6E9D-7CBD-43BA-A7E0-CD1295466903Q38025001-1364A3AA-D486-4903-88A6-DF1F0CCC8AF5Q38163949-3678C774-B463-4A39-B532-C3342AA53339Q38181145-37690D5D-D7B7-423C-8090-1EF6F0557844Q38398596-2A95F3FD-835E-4772-9249-89AF00E8EE5BQ38661592-1484A0CE-D69B-4062-B2D3-DF77F739D8F3Q38745850-4A66BF88-7BAC-44F3-A6A4-BBDF7D116A5AQ38752235-A2DE4BF0-D203-451F-AF84-88BB3D0EE1CAQ38767484-03175421-D9A7-43EC-851F-AF667BAED767
P2860
V-ATPase inhibitors and implication in cancer treatment.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
V-ATPase inhibitors and implication in cancer treatment.
@en
V-ATPase inhibitors and implication in cancer treatment.
@nl
type
label
V-ATPase inhibitors and implication in cancer treatment.
@en
V-ATPase inhibitors and implication in cancer treatment.
@nl
prefLabel
V-ATPase inhibitors and implication in cancer treatment.
@en
V-ATPase inhibitors and implication in cancer treatment.
@nl
P50
P1476
V-ATPase inhibitors and implication in cancer treatment
@en
P2093
Francisco Barros-Angueira
José Manuel Gándara Rey
P304
P356
10.1016/J.CTRV.2009.08.003
P577
2009-09-15T00:00:00Z